Literature DB >> 3765240

Clinical significance of erythropoietin levels in renal carcinoma.

U O Nseyo, P D Williams, G P Murphy.   

Abstract

The bioassay using the polythemic mice demonstrated persistent erythropoietin (Ep) activity in 24 renal carcinoma patients. Eight patients without clinical evidence of renal carcinoma had Ep levels that were slightly higher than those of controls, suggesting the possibility of occult disease. Increased levels of Ep were noted in 5 patients with other genitourinary carcinomas. This selective study reaffirms the value of Ep as a biologic marker in some renal cell cancers, and occasionally in other genitourinary tumors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3765240     DOI: 10.1016/0090-4295(86)90011-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta].

Authors:  M Schenck; C Börgermann; T Jäger; F vom Dorp; H Sperling; H Rübben; G Lümmen
Journal:  Urologe A       Date:  2007-05       Impact factor: 0.639

2.  Successful treatment of erythropoietin-producing advanced renal cell carcinoma after targeted therapy using sunitinib: Case report and review of the literature.

Authors:  Kosuke Ueda; Shigetaka Suekane; Katsuaki Chikui; Makoto Nakiri; Fukuko Moriya; Tokumasa Hayashi; Jiro Miyajima; Kei Matsuoka
Journal:  Mol Clin Oncol       Date:  2012-08-03

3.  The Disturbed Iron Phenotype of Tumor Cells and Macrophages in Renal Cell Carcinoma Influences Tumor Growth.

Authors:  Matthias Schnetz; Julia K Meier; Claudia Rehwald; Christina Mertens; Anja Urbschat; Elisa Tomat; Eman A Akam; Patrick Baer; Frederik C Roos; Bernhard Brüne; Michaela Jung
Journal:  Cancers (Basel)       Date:  2020-02-25       Impact factor: 6.639

Review 4.  Functional significance of erythropoietin in renal cell carcinoma.

Authors:  Christudas Morais; David W Johnson; David A Vesey; Glenda C Gobe
Journal:  BMC Cancer       Date:  2013-01-10       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.